Abstract
Purpose. The FLEP regimen (5-FU, LV, ETP, and CDDP) has been recommended as a combination chemotherapy to control advanced and recurrent gastric cancer. We performed a phase II study of this regimen in 49 patients with advanced gastric cancer.
Methods. The treatment regimen consisted of: 5-FU at 370 mg/m2 (days 1–5, i.v. 24 h); LV at a dose of 30 mg (days 1–5, i.v. bolus); and ETP and CDDP each at 70 mg/m2 (days 7 and 21, i.a. 2 h), which was repeated every five weeks.
Results. The overall response rate was 40.8% (20/49 patients) and the median survival time was 12.6 months (range 1.1–41.8). The adverse events were Grade 3/4 leukocytopenia (16.3%), Grade 3/4 thrombocytopenia (8.2%), Grade 3 nausea and/or vomiting (4.1%), and Grade 3 stomatitis (2.0%).
Conclusions. Based on the encouraging response rate and prognosis, we recommend applying the FLEP regimen to patients with primary advanced gastric cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Mochizuki, F., Fujii, M., Kasakura, Y. et al. Combination chemotherapy comprising 5-fluorouracil, leucovorin, etoposide, and cis-diamminedichloroplatinum for the treatment of advanced gastric cancer. J Cancer Res Clin Oncol 128, 493–496 (2002). https://doi.org/10.1007/s00432-002-0369-7
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00432-002-0369-7